Ant Cancer Drugs

southdelhipharma.com is a leading supplier and exporter of anti-cancer drugs. We are the leading supplier of leading cancer drug producers in India and is committed to giving you the highest quality products and services.

South delhi pharma has equipment leading the anti-cancer drugs as Geftinat, Veenat, Erlonat, Tarceva, Gefitinib, Imatinib, Baraclude, EntecavirSome of the anti-cancer drugs and their characteristics and specialty to cure cancer is described below.

Veenat: A medicine to combat cancer, Veenat is a protein-tyrosine kinase inhibitor, which may inhibit platelet growth and stem cells. Veenat is a prescription drug and should be used under proper medical supervision and instruction.

GEFTINAT-GEFTINAT is used for the treatment of locally advanced or metastatic non-small cell lung cancer. Consult your doctor suggest the dose that is appropriate for your condition

Tarceva is a medicine used to treat non-small cell lung cancer, pancreatic lymph nodes, cancer and several other types of cancer. It is a tyrosine kinase inhibitor that works on epidermal growth factor receptor (EGFR). Marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche.

Gefitinib (trade name Iressa) is a medicine used for the treatment of certain types of cancer. EGFR inhibitor Gefitinib is a like erlotinib, which terminates the signaling through the epidermal growth factor receptor in target cells. It is marketed by AstraZeneca and Teva. Gefitinib is the first selective inhibitor of the epidermal growth factor receptor's (EGFR) tyrosine kinase domain. Gefitinib is thus an EGFR inhibitor. Target protein (EGFR) is also sometimes referred to as Her1 or ErbB-1 depending on the literature source

Imatinib is a medicine used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America) as its mesylate salt, imatinib mesilate (INN). It is used in treating chronic myeloge nous leukemia (CML.), gastrointestinal stromal tumours (GISTs) and some other diseases. In 2011, has been FDA approved Gleevec for answering any claims linked to the ten different cancers. In CML., tyrosine kinase enzyme operating system files hang in his enabled form; imatinib binds to the site of the tyrosine kinase activity and prevents its activity.

Imatinib is the first member of a new class of agents that Act by specifically inhibiting a certain enzyme, which is characteristic of a particular cancer cell, rather than not specifically inhibiting rapidly dividing cells kill all and served as a model for other targeted therapy modalities through tyrosine kinase inhibition.

Posted in cancer

Related Articles